We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Is Carotid Intima-media Thickness Affected by A1C Variability?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00842972
First Posted: February 12, 2009
Last Update Posted: September 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Yonsei University
  Purpose
This study was conducted to evaluate the effect of A1C variability on the progression of carotid artery intima-media thickness in type 2 diabetic patients.

Condition
Type 2 Diabetes A1C Variability

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Yonsei University:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   34 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
typeII, Fluroscopy in carotid once a year during 2 years.
Criteria

Inclusion Criteria:

  • type II
  • fluoroscopy in carotid once a year during 2 years

Exclusion Criteria:

  • type 1 diabetes
  • history or clinical evidence of coronary artery disease or cerebral or peripheral vascular disease
  • the presence of albuminuria (defined as 24 hour urine albumin excretion ≥ 30 mg)
  • renal dysfunction (defined as creatinine blood level ≥ 2.0 mg/dL)
  • hepatic dysfunction (defined as alanine aminotransferase and/or aspartate aminotransferase blood level ≥ 3 × upper normal limit)
  • smoking within the past 3 months prior to commencement of the study
  • use of any medication likely to alter IMT such as calcium channel blocker, thiazolidinedione, antiplatelet agent (clopidogrel, cilostazol)
  • use of glucocorticoid
  • pregnancy
  • severe concomitant disease such as cancer
  • infection
  • Cushing's syndrome
  • acromegaly, or any other disorder likely to alter glycemia
  • primary hypercholesterolemia
  • hypothyroidism or hyperthyroidism
  • use of any hormonal drugs
  • alcoholism or drug abuse
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Ahn, Chul Woo, Gangnam Severance Hospital
ClinicalTrials.gov Identifier: NCT00842972     History of Changes
Other Study ID Numbers: 3-2006-0005
First Submitted: February 11, 2009
First Posted: February 12, 2009
Last Update Posted: September 15, 2009
Last Verified: September 2009